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Abstract Recent advances in our understanding of the
molecular biology of salivary gland neoplasms have yiel-
ded diagnostic targets and potential therapeutic targets that
have started to change our approach and choice of treat-
ment strategies. Currently, these options are mainly
investigated in recurrent and metastatic salivary gland
cancer (SGC). Although the results of both cytotoxic and
targeted molecular biological systemic therapy for locore-
gional recurrence and distant spread of SGC remain largely
unpredictable, targeted therapy can be the treatment of
choice in selected cases today. Molecular analysis is
required as part of the diagnostic workup to help select
patients with recurrent and metastatic SGC who may
benefit from targeted or standard treatment regimens.
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Introduction
The annual incidence of salivary gland carcinomas ranges
from 4 to 135 new patients per 106 people, with the highest
incidence rates reported in Greenland and the Canadian
Arctic [1]. The US incidence is reported as 10 new patients
per 106 per year [2], and somewhat lower European inci-
dences, such as reported in Finland, Belgium, The Neth-
erlands and the UK, amount to about 6–7 per 106 per year
[3–6]. The major salivary glands give rise to 90–95 % of
these tumors, where 70 % occur in the parotid and
20–25 % in the submandibular and sublingual glands. Less
than 10 % arise in the minor salivary glands [3, 4, 7–9].
This review focuses on recent advances in our under-
standing of the molecular biology of these rare cancers and
aims at updating the reported experience with cytotoxic
and targeted molecular biological agents in the recurrent—
metastatic disease setting.
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Diagnosis: Histotyping and Grading
In 2005, the World Health Organization (WHO) published
the current reference classification featuring 24 different
types of salivary gland cancer (SGC) [10]. The pathologist
combines light microscopic features and immunohisto-
chemistry to (1) assign a specific tumor to one of the cat-
egories in this classification (histotyping); (2) describe
negative prognostic features (lymphovascular invasion,
positive resection margins, perineural growth, etc.); and (3)
for specific subtypes, to grade the tumor. Molecular
markers are becoming increasingly important in the diag-
nostic fine-tuning of SGCs.
Histotyping
There is frequently no uniform relationship between histotype
and biological behavior [11]. Only population-based studies
give a true reflection of the distribution of the 24 histotypes. In
such population-based studies, the majority of major SGCs are
acinic cell carcinoma (AcCC: 15–17 %), adenoid cystic car-
cinoma (AdCC: 16–27 %), and mucoepidermoid carcinoma
(MEC: 14.5–19 %) [6, 12]. In most studies of minor SGCs,
AdCC and MEC account for up to 89 % of histologic types,
and AdCC (32–71 %) and MEC (15–38 %) far outnumber
adenocarcinoma Not Otherwise Specified (ACNOS), AcCC,
polymorphous low grade adenocarcinoma (PLGA), epithelial
myoepithelial carcinoma, and carcinoma ex-pleomorphic
adenoma (CXPA) [9]. Histotyping of SGCs is challenging,
and marked by high reclassification rates following slide
review of historical series. Examples are the 29 % reclassifi-
cation rate resulting from application of a new histologic
classification system as reported by van der Wal et al. [13] and
a 22 % reclassification rate as reported in our own series [14].
A substantial interobserver variability between pathologists
also exists [15]. Reclassification, interobserver variability,
geographic variation and referral bias all contribute to dis-
parities in the published histology distribution. For clinical
purposes, we routinely divide the different histotypes into
clinically low-grade (AcCC, PLGA and low-grade MEC),
intermediate-grade (epithelial myoepithelial carcinoma and
AdCC) and high-grade carcinomas (salivary duct carci-
noma—SDC, ACNOS, high-grade MEC, CXPA and undif-
ferentiated carcinoma). However, also the clinical grade
assignment does not always parallel clinical behavior. This
‘‘clinical grading’’ has to be distinguished from the ‘‘histo-
pathological’’ or ‘‘optical’’ grading described in the next
paragraph.
Histopathological Grading
Optical grading by the pathologist is an attempt to explain
variable biological behavior within tumors of the same
histotype and is well established in the three most frequent
salivary gland carcinomas: MEC [15–17], AcCC [18] and
AdCC [19, 20]. However, grading shows poor inter- and
intraexaminer consistency with a low independent prog-
nostic power in multivariate analysis, because grading
parallels other important prognostic factors that are more
reliable to reproduce such as age, stage, perineural growth
and irradical surgery [8].
Molecular Biology in Diagnosis and Prognosis
Molecular markers are a main focus of current salivary
gland tumor research. As optical grading suffers from
interobserver variation and is collinear with many other
strong clinicopathological factors, molecular markers are
being investigated for their potential prognostic role and
may prove more reliable in predicting outcome. They are
also under study as therapeutic targets.
Cell Cycle-Based Proliferation Markers
The endpoint of the accumulation of genetic and epigenetic
changes that leads to deranged growth is reflected by the
expression of cell cycle-based proliferation markers. Their
expression parallels the number of cells going through the
cell cycle toward division. Among cell-cycle based pro-
liferation markers in SGC, well studied are the expressions
of Ki-67, an anti-apoptotic nuclear antigen in proliferating
cells [21–23], proliferating cell nuclear antigen (PCNA, a
co-factor of DNA polymerase) [24, 25], human telomerase
reverse transcriptase (hTERT) [26] and AgNOR (argyro-
phylic nucleolar organizer region-associated proteins) [27,
28], as well as TUNEL [terminal deoxynucleotidyl trans-
ferase (TdT)-mediated dUTP-biotin nick end labeling]
assays that identify DNA breaks in apoptotic cells [29].
The most widely used of these is the general overall pro-
liferation marker Ki-67, which is widely applicable and
correlates well with biological behavior [21]. Together
with age and tumor stage, the Ki-67 index is an important
and independent prognostic factor on multivariate analysis,
irrespective of tumor subtyping, grading or morphological
appearance of the salivary gland tumor [30••].
Separately Studied Genetic and Epigenetic Changes
At the basis of the deranged growth (that is reflected by the
cell cycle-based proliferation markers just mentioned) is an
accumulation of genetic and epigenetic changes, which are
all elements of the cascade that ultimately results in
uncontrolled growth. Many of these elements have been
studied separately, but the prognostic value can be con-
firmed only if they remain independent on multivariate
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analyses. Some of these markers have also been investi-
gated as therapeutic targets, and these are tabulated in
Table 1 [31–43]. For the description of these markers, we
grouped them using a similar structure as in our previous
review paper on parotid carcinoma [8].
Growth Factor Receptor Proteins and Their Ligands
Stem cell factor receptor (c-KIT, a transmembrane tyrosine
kinase), angiogenesis-related growth factor receptors
(VEGF-R, PDGF-R, bFGF-R, IL-8, PlGF, TGFb, EphA2),
nerve growth factor (NGF), the ErbB/HER family of
human epidermal growth factor receptors (EGFR also
named HER-1 or ErbB-1; HER-2 or HER2/Neu or ErbB-2;
HER-3 or ErbB-3; HER-4 or ErbB-4), insulin-like growth
factors (IGF–I/II) and receptor (IGF-1R) and receptor
tyrosine kinase MET and its ligand hepatocyte growth
factor can be put in this category.
c-KIT is detected in 80–94 % of AdCC [44] and in
100 % of lymphoepithelial-like salivary gland carcinomas
and myoepithelial carcinomas, and in a subset of other
tumors as well [44]. In AdCC, the relation between high
c-KIT expression ([50 %) and grade has been widely
discussed and remains unresolved. In one study this feature
was significantly more common in grade 3 or solid-type
AdCC [45], but Freier et al. [46] found the opposite: high
expression only in cribriform and tubular AdCC.
For angiogenesis-related growth factor receptors, Lim
et al. [47] describe the prognostic value for VEGF
expression, which is found in many SGCs. In multivariate
analyses, VEGF expression was associated with advanced
stage and worse DSS [48]. Greater expression of EphA2, a
receptor tyrosine kinase involved in angiogenesis, and its
ligand ephrin A1 has recently been described in AdCC,
where expression correlates to microvessel density, TNM
stage, perineural invasion and vascular invasion. This
expression is significantly greater in solid type AdCC than
in the cribriform and tubular types [49].
In the human epidermal growth factor receptor family,
EGFR identification and overexpression correlate with
aggressiveness in MEC [50], SDC [51, 52] and AdCC [50,
51]. Although EGFR protein expression is common in
SGC, it is not associated with gene amplification [53].
Activating mutations of EGFR are rare in SGC, but when
present, they may be linked to good response to anti-EGFR
therapy in a way similar to what is observed in non-small
cell lung cancer [53]. A recent study by Lee et al. [54] was
not able to link the expression of EGFR, c-KIT and VEGF
to prognosis in AdCC. HER-2 has been found overex-
pressed in AdCC, SDC [52, 55, 56], CXPA [57] and about
30 % of MEC [25, 38, 50, 58, 59]. Furthermore, it is a
negative prognostic marker in multivariate analysis, inde-
pendent of histopathological grade, tumor size and
involvement of regional lymph nodes [59]. Aggressively
behaving AdCCs also display HER-3 expression [50].
Increased expression of NGF, besides increased VEGF
expression, has been described in AdCC, possibly
accounting for its neurotropism [60]. In the same line,
recently Ivanov et al. [61••] observed overexpression of a
large cluster of neuronal genes grouped around TrkC/
NTRK3, a tyrosine kinase neurotrophic receptor associated
with neurogenesis and cancer, in AdCC. This finding
suggests that AdCC aberrantly expresses genes involved in
neural stem cell differentiation.
The receptor tyrosine kinase MET and its ligand, the
hepatocyte growth factor, activate different cellular sig-
naling pathways leading to tumor cell proliferation,
migration, motility and invasion. In SGC, aberrations of
genomic MET are associated with lymphatic spread and
are characteristic for high-risk tumors with poor overall
survival [62•]. Multivariate analysis showed that aberration
of MET is a very strong predictor of lymph node metas-
tasis, even stronger than the established criteria of tumor
size and grade [63].
Cell Cycle Oncogenes
The above-mentioned growth factor-receptor interaction
activates cell cycle oncogenes, including sex-determining
region Y-box 4 and 10 (SOX-4, SOX-10), nuclear factor
jB (NFjB) [64, 65], human rat sarcoma viral oncogene
homolog (H-RAS), phosphatidylinositol 3 phosphate
kinase/serine-threonine protein kinase Akt (PI3 K/AKT)
[65], sarcoma (Schmidt-Ruppin A-2) viral oncogene
homolog (Src), signal transducer and activator of tran-
scription 3 (STAT3), mammalian target of rapamycin
[mTOR, activated by AKT, regulating protein synthesis
depending on nutrient availability and negatively regulated
by the tumor suppressor gene phosphatase and tensin
homolog (PTEN)], peroxisome proliferator-activated
receptor gamma (PPARc) [66] and cyclin D1.
Table 1 Molecular targets and bullets in SGC
Molecular target SGC type Molecular therapy
c-KIT AdCC Imatinib [31, 32, 34–36, 42];
sunitinib [133]
EGFR, ErbB-1 All types Cetuximab [51];
gefinitib [134]
HER2/neu, ErbB-2 All types Trastuzumab [39, 40, 135•];
lapatinib [33]
NFjB—proteasomes
degrading its
inhibitor (I-jB-a)
AdCC Bortezomib [41]
VEGF AcCC Axinitib [136]
Modified from [9] with permission
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In a large microarray analysis of AdCC, Frierson et al.
[67] found that SOX-4 was the most significantly overex-
pressed cell cycle oncogene. Furthermore, increased
apoptosis following SOX-4 knockdown suggests that this
oncogene exerts its activity via downregulation of inhibi-
tors of the NFjB pathway (inhibitor protein I-jB-a) and by
upregulation of apoptosis inhibitors such as survivin [68].
More recently, the transcriptional factor SOX-10, normally
only expressed during salivary gland differentiation, was
found markedly upregulated in a great majority of AdCC
cells [69]. Mutations of H-RAS are observed in CXPA
[70], ACNOS [71] and almost half of MECs, where the
frequency of H-RAS mutations parallels tumor grade [72].
Cyclin D1 seems frequently overexpressed in AdCC and
MEC and correlates to prognosis [73, 74]. In MEC, high
cyclin D1 expression follows inactivation of secreted
frizzled-related proteins (SFRPs) by hypermethylation
[74]. Nuclear STAT3 expression seems to play a role as a
tumor suppressor in the absence of EGFR, HER-2 and
survivin in SGC [52]. RUNX3, a tumor suppressor gene
that, when active, facilitates TGF-beta to play its apoptotic
role, appears silenced by hypermethylation in AdCC [75].
Expression of PDCD4 (programmed cell death 4), a
recently described tumor suppressor gene inhibiting neo-
plastic transformation and tumor promotion/progression, is
downregulated in the majority of AdCCs. Decreased
PDCD4 expression is also significantly associated with the
clinical stage of the disease and poor prognosis. Multi-
variate analysis demonstrated that PDCD4 expression is an
independent risk factor for AdCC [76•]. Suprabasin
(SBSN), a novel oncogene in AdCC, plays important roles
in maintaining cell proliferation and invasive metastatic
capability in AdCC. Moreover, the expression of SBSN is
upregulated by CpG island demethylation, and hypome-
thylation of SBSN is significantly more frequent in AdCC
than in normal salivary gland tissues [77]. RB1-inducible
coiled-coil 1 (RB1CC1) is a positive regulator for the ret-
inoblastoma tumor suppressor (RB1) pathway, and its
expression in SGCs appears to imply better prognosis,
analogous to what has been shown for breast cancer [78].
Expression of ERBB3-binding protein 1 (EBP1), a mole-
cule with multiple roles in cell proliferation and differen-
tiation, was found to be inversely correlated with local
invasion and distant spread of AdCC. Patients with lower
EBP1 levels had poorer long-term survival than those with
higher EBP1 expression, and this follows the upregulation
of E-cadherin by EBP1, inhibiting the migration and
invasiveness of AdCC [79]. The PI3K/AKT/mTOR
(mammalian target of rapamycin) axis plays a critical role
in tumorigenesis. Dysregulation of this molecular pathway
involves alterations of AKT, mTOR, PTEN and various
upstream tumor-associated growth factors (EGFR, HER-2,
PDGF and VEGF) [80]. Loss of PTEN goes along with
stimulation of the PI3K pathway, promoting cell survival
and tumor growth, resulting in cell migration and metas-
tasis by deregulation of cell interactions with the extra-
cellular matrix. Loss of PTEN has been described in a
subset of highly malignant SGCs and was assocciated with
high levels of EGFR and HER2 [81•]. Recently, deletion of
PTEN was found a strong predictor of neck node metas-
tasis, remaining so in multivariate analysis [63]. Efforts are
underway at targeting the PI3K/AKT pathway by blocking
mTOR with temsirolimus [82].
Pleomorphic adenoma gene 1 (PLAG1) is a specific
proto-oncogene found in a large percentage of pleo-
morphic adenomas and is transcribed and overexpressed
following a t(3;8)(p21;q12) chromosome translocation
resulting in b-catenin-promoter swapping. This causes
deregulated expression of PLAG1 target genes by the
IGF-II IGFIR mitogenic signaling pathway [83]. Another
fusion oncogene, MEC translocated 1 gene with exons
2–5 of the mastermind-like gene 2(MECT1-MAML2);
t(11;19)(q14–21;p12–13) [84] is transcribed into a fusion
protein that was initially thought to be exclusively seen
in low-grade MEC histology [85, 86]. However, high-
grade fusion-positive MECs associated with advanced-
stage lethal disease have now been described [87]. For
AdCC, a recurrent reciprocal translocation of
t(6;9)(q22–23; p23–24) resulting in fusion gene partners
comprising the MYB gene and the transcription factor
NFIB (previously reported in AdCC of the breast, lac-
rimal and ceruminal glands) has now been described. In
both fusion-positive and a subset of fusion-negative
AdCCs, high expression of the transcript Myb was
found, suggesting this as a potential target for new
therapies [88].
Proteins Involved in DNA Damage Repair
p53 and ERCC1 (excision repair cross-complementation
group 1) belong in this category. p53 expression [89] and
p53 mutations in AdCC are generally associated with
worse outcome [90], but a large Finnish multivariate ana-
lysis failed to confirm this information as having additional
value over a classical clinicopathological multivariate
model. This large study however did not focus on the
AdCC subgroup but studied all SGC types [91].
Proteins Involved in Apoptosis
The Bcl-2 group contains pro-apoptotic proteins such as
Bax, Bad and Bak and anti-apoptotic proteins such as
Bcl-2, Bcl-xL and survivin. High Bcl-2 expression in SGC
relates to poor prognosis and advanced T and N classifi-
cation [92]. Nuclear survivin expression indicates aggres-
sive SGC with worse prognosis [52].
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Proteins involved in cell-cell adhesion (hemidesmosome
proteins B180 and B230, E- and N-cadherin, CDH12, a-
catenin, mammalian ENA, CD44 and CD24) [93–98],
migration (matrix metalloproteinase, heparanase, CD147
or extracellular matrix metalloproteinase inducer
or Emmprin) [11, 99–102] and epithelial-mesenchymal
transition (NBS-1 and snail)
Matrix metalloproteinase 9 (MMP-9) degrades type IV
collagen, a major component of basement membranes in
human tissues, and allows the tumor cells to break through
the site of the primary tumor, leading to invasion and
metastasis. MMP-9 was recently found to be overexpressed
in SDC, together with tumor cell-associated extracellular
MMP inducer, CD147, which regulates the expression
level and activity of MMP-9 and MMP-2. High expression
of CD147 and MMP-9 was significantly correlated with
invasion, metastasis, shorter progression-free survival and
shorter overall survival (poor prognosis) compared with
SDC patients with low CD147/MMP-9 expression [102].
Recent research identified an association between ILK
(integrin linked kinase) and epithelial-mesenchymal tran-
sition markers in adenoid cystic carcinoma (AdCC). ILK
plays a key role in cell-extracellular matrix interactions,
regulating cell proliferation, apoptosis, differentiation and
migration. Positive expression of ILK correlates strongly
with solid-type AdCC, advanced TNM stage and increased
risk of recurrence. Moreover, upregulation of Snail and
N-cadherin and downregulation of E-cadherin correlated
significantly with ILK overexpression and a neural invasive
phenotype. Through epithelial-mesenchymal transition by
upregulation of Snail, downregulation of E-cadherin and
upregulation of N-cadherin, ILKs may have an important
role in progression and metastasis in AdCC [103].
Estrogen, Progesterone and Androgen Receptors [51, 66,
104••]
Estrogen receptors have been described in AdCC, whereas
androgen receptors have been the target of hormonal
therapy in SDC. In a study that examined 139 cases of
SGC, androgen receptor expression was found in 13 %, but
no expression of estrogen or progesterone receptor was
detected [105•].
Markers for Lymphangiogenesis
Podoplanin (T1a-2, aggrus or gp36) is a small mucin-like
protein and its function is related to tissue development and
repair. It is specifically expressed in lymphatic endothelial
cells and is used as a specific marker for lymphangiogen-
esis. It is also expressed in certain tumor cells and is
associated with migration/invasion in cervix and oral
squamous cell carcinoma. Recently, Podoplanin was found
to be overexpressed in a subset of salivary gland AdCCs
(32.5 % of tumors). Overexpression was significantly
associated with disease-free survival and distant metastasis,
although it was not associated with recurrence and overall
survival [106].
Viral Etiology
Recently the interesting hypothesis was put forward that
the hCMV virus is implied in the oncogenesis of MEC.
This awaits further validation in larger series, but the
authors found the viral protein expressed in almost all cases
studied [107•].
Transcription Factors
In AdCC, significant epigenetic changes (hypermethyla-
tion) were observed at the transcriptional start sites of
genes that encode for the transcription factor Engrailed
homeobox 1 (EN1), which plays an important role in the
development of the central nervous system. Hypermethy-
lation of EN1 correlates with histologic tumor grade, tumor
location and final patient outcome in AdCC [108]. More-
over, EN1 protein expression was typical for solid type
AdCC and implied a significantly lower survival rate,
making EN1 a potential biomarker in AdCC [109].
Treatment with Cytotoxic Chemotherapy
in the Palliative Setting
In advanced SGC, no standard systemic treatment is
available. Cytotoxic chemotherapy is generally used in the
context of a palliative therapy, based on level 3 evidence
(case-control or cohort studies). The data supporting the
use of chemotherapy are scarce, because trials involve
small populations with important heterogeneity regarding
the histology, prior systemic therapies and proportion of
patients with locoregional recurrence versus distant
metastasis. Moreover, the majority of SGCs have a slow
growth pattern, making it difficult to assess the response of
the tumor to chemotherapy.
Monotherapy (Single-Agent Chemotherapy)
Cisplatin is the most extensively studied single-agent
chemotherapy for advanced SGC. The largest phase II
study included 25 patients with AdCC, MEC and ACNOS
and showed a mean response rate of 18 %, response
duration between 5 and 9 months, and a median overall
survival time of 14 months [110]. On the other hand, De
Haan et al. [111], including ten patients with advanced
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AdCC, observed no objective responses: five patients
showed stabilization of their disease for a median duration
of 20 months.
In AdCC, mitoxantrone, epirubicin and vinorelbin all
appear to have activity as a single agent. In a study
including 32 AdCC patients, mitoxantrone induced a par-
tial response in four patients, lasting from 3 to 13 months,
and 22 patients had stable disease [112]. Although treat-
ment with epirubicin yielded a rapid improvement in dis-
ease-related symptoms in 29 % of patients in a phase II
trial including 20 patients with advanced or recurrent
AdCC, the response rate remained low (10 %) and the
median time to disease progression short (16 weeks) [113].
Vinorelbin has moderate activity in AdCC and ACNOS
with overall response rates of 20 %, median partial
response duration of 6 months, median time to disease
progression of 5 months, median stable disease duration of
3.5 months and median overall survival of 8.5 months
[114]. In a study by Gilbert et al., paclitaxel did not show
any activity in AdCC, but it appears to provide some
objective responses in MEC and ACNOS [115]. Gemcita-
bine monotherapy showed no objective responses in AdCC
[116].
Combination Therapy
The most studied regimen in the treatment of advanced
SGC is CAP (cyclophosphamide, doxorubicin and cis-
platin) [117]. A phase II trial by Licitra et al. [118], treating
22 patients with advanced SGC (AdCC and non-AdCC),
achieved partial responses in only six patients, with an
overall response rate of 27 %. In our patients with meta-
static ACNOS treated with CAP, we observed a 60 %
response rate, but the responses were generally short-lived
with a median time to progression of 6.6 months [119].
Tsukuda et al. [120] documented a 36 % response in 14
patients with ACNOS or AdCC treated with CPPr (cyclo-
phosphamide, cisplatin and pirabucin, a less cardiotoxic
anthracycline analog). In a series of 17 patients treated with
PAF (cisplatin, doxorubicin and 5-fluorouracil), overall
response was 35 % (12 % complete, 23 % partial
response), with response duration of 6 up to 15 months but
no survival advantage [121]. A combination treatment of
cisplatin, epirubicin and 5-fluorouracil (PEF) did not do
better than cisplatin monotherapy (one partial response out
of eight patients) [122]. Evaluating FACP (5-fluorouracil,
doxorubicin, cyclophosphamide and cisplatin) in 17
patients with advanced SGC, the objective response rate
was 50 % (44 % partial, 6 % complete response) with a
median duration of 7 months, but with a higher toxicity
than three-agent regimens [123]. A small randomized study
compared vinorelbine with a combination of vinorelbine-
cisplatin (PV) in 16 patients with recurrent SGC of all three
major histologic subtypes. Overall response of the PV
regimen was 44 %. Median duration of complete response
was 15 months and of partial response 7.5 months, making
PV better than vinorelbine in monotherapy. Compared to
CAP, PV could be less toxic and equally effective [114]. A
combination of carboplatin and paclitaxel only achieved
two partial responses in 14 patients with SGC, resulting in
a median survival of 12.5 months [124].
More recently, Laurie et al. evaluated a gemcitabine-
cisplatin/carboplatin (GP) regimen in 33 patients with
advanced SGC. The response rate was 24 %, median
response duration 6.7 months. Thus, GP demonstrates
modest activity in advanced SGC but no advantage over
other cisplatin-based regimens (e.g., CAP) [125].
In conclusion, whether or not combination chemother-
apy is better than monotherapy for SGC is still uncertain.
Combination regimens generally result in higher response
rates at the cost of additional toxicity, but fail to improve
survival [126]. A recent high-quality meta-analysis focus-
ing on locally recurrent or metastatic AdCC reaches the
same conclusion [127••]. This study evaluated the activity
of combination chemotherapy in 143 patients enrolled in
17 trials. In 14 studies, cisplatin-based regimens led to
objective responses in 29 of 118 patients (response rate
25 %). Response duration ranged widely, from 6 to
77 months.
Treatment with Cytotoxic Chemotherapy
in the Curative Setting
Recently, two reports documented the benefit of a post-
operative platinum-based concomitant chemoradiation
scheme for high-risk major salivary gland carcinomas [128,
129].
These are preliminary reports that still need validation
given the clearly higher toxicity this approach entails.
Treatment with Targeted Therapies
The explored targeted therapies are listed in Table 1.
Imatinib
Although c-KIT is overexpressed in up to 94 % of AdCCs,
results of treatment with imatinib (c-KIT tyrosine kinase
inhibitor) are disappointing. Imatinib as a single agent was
evaluated in 5 studies including 54 patients [31, 32, 34, 42,
130]. Stable disease was observed in 19 patients (35 %).
Only two objective responses were reported (3.7 %), both
in a study requiring progressive disease and high c-KIT
expression for inclusion [42]. One phase II study,
Curr Otorhinolaryngol Rep
123
evaluating the combination imatinib/cisplatin in 28 patients
with locally advanced and metastatic AdCC, showed a
partial response in 3 of 28 patients, while 19 patients
(68 %) had disease stabilization [131].
Lapatinib
Lapatinib, a dual inhibitor of EGFR and HER-2 tyrosine
kinase activity, was evaluated in 40 patients with pro-
gressive metastatic or recurrent SGC with proven EGFR/
HER-2 overexpression. Although no objective responses
were seen, disease stabilization for at least 6 months was
observed in 13 patients (32.5 %). Because disease pro-
gression was needed to meet the inclusion criteria, the
disease stabilization was likely due to the effect of lapati-
nib [33].
Gefitinib
Despite the common EGFR expression in SGC, the orally
active EGFR tyrosine kinase inhibitor gefitinib performs
poorly in patients with advanced SGC. A phase II study
including 28 patients with advanced SGC reported no
objective responses and stable disease in 14 patients, with a
median duration of 3 months. Of the latter, 13 patients had
AdCC, typically behaving in an indolent way, making
‘‘stable disease’’ an unreliable endpoint [132].
Bortezomib
Bortezomib inhibits the proteasome that normally degrades
the NFjB inhibitor (I-jB-a). In this way, NFjB, related to
angiogenesis and poor patient outcome, is inhibited. Bort-
ezomib was tested in a phase II trial including 24 patients
with recurrent or metastatic AdCC, but no objective
responses were observed. Fifteen of 21 evaluable patients
(71 %) showed disease stabilization for a median duration
of 4.2 months and an overall survival of 21 months. In ten
patients, doxorubicin was added at disease progression,
leading to one partial response and five disease stabiliza-
tions (median duration, 5.2 months) [41].
Sunitinib
The antitumor activity of sunitinib, a multitarget inhibitor
of VEGF-R, PDGF-R, c-KIT, ret proto-oncogene (RET)
and FMS-like tyrosine kinase 3 (FLT3), was assessed in
a phase II study. In 13 patients with recurrent and/or
metastatic AdCC, no objective responses were seen, and
11 patients showed stable disease, in 8 patients stable for
minimally 6 months. Median time to progression was
7.2 months, while median overall survival was
18.7 months [133].
Cetuximab
The anti-EGFR monoclonal antibody cetuximab was
evaluated in a phase II trial including 30 patients with
advanced SGC [37]. No objective responses were reported,
but stable disease was recorded in 24 (80 %) patients,
lasting for more than 6 months in 15 of them. Molecular
analysis showed no EGFR gene amplification, and just
12 % of AdCCs showed an increase in the EGFR gene
copy number. Clauditz et al. confirm this finding that,
although EGFR protein expression is common in SGC,
EGFR gene amplification and activating mutations are rare.
Several studies, e.g., in non-small cell lung cancer, suggest
a predictive role of the EGFR copy number for anti-EGFR
therapy response, so selected cases of patients with
advanced SGC and an increased EGFR copy number might
derive more benefit from anti-EGFR therapy [53].
Trastuzumab
Trastuzumab, a monoclonal antibody interfering with the
HER-2 receptor, was tested for the first time in a phase II
trial by Haddad et al. in advanced SGC overexpressing
HER-2. The study closed early because of the low rate of
HER-2 overexpression in the SGC screened for study
entry. One objective partial response in a patient with MEC
lasted for more than 2 years, but the rest showed disease
progression after a median time of 4.2 months, so the
conclusion was that trastuzumab is not active in advanced
SGC [39]. Nabili et al. [40] reported one complete response
in three patients treated with trastuzumab for progressive
SDC. Limaye et al. [43] recently retrospectively assessed
trastuzumab combined with paclitaxel and carboplatin in
an adjuvant or palliative setting in 13 patients with HER-2
positive SDC. All patients with metastatic disease (5
patients) responded for a median duration of 18 months;
one patient achieving a complete response remained free of
disease 52 months after initiation of therapy.
Conclusion
Recent advances in our understanding of the molecular
biology of SGC have yielded diagnostic targets and also
potential therapeutic targets for patients with locally
recurrent or metastatic disease, but to date, the results of
systemic treatment by means of cytotoxic chemotherapy or
targeted molecular therapies remain modest. At best,
temporary, usually partial, disease response or stabilization
can be achieved before disease progression occurs. Multi-
institutional and international collaborative efforts to col-
lect and share tumor samples through tissue banks will be
necessary to provide the tissue material needed for
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assessment and validation of diagnostic and prognostic
molecular biological advances and to perform multicenter
trials of potentially promising new treatment strategies.
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